Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

NCT05408845 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT05408845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05408845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Lead sponsor
NRG Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
March 3, 2023
Completion date
July 31, 2032
Enrollment
146 (estimated)
Sites
152

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic salivary gland carcinoma, recurrent salivary gland carcinoma, stage iii major salivary gland cancer ajcc v8, stage iv major salivary gland cancer ajcc v8, unresectable salivary gland carcinoma